Recent Posts

Pages: [1] 2 3 ... 10
1
EXTREME PICKS / Hampshire Group Ltd. HAMP
« Last post by Extreme Stocks on June 05, 2016, 08:39:02 AM »
$HAMP $0.065 MOST UNDERVALUED STOCK on PLANET, Easily Valued @ $5.00 to $8.00 >> A/S 13.3m, O/S 8.7m, Float 700k with 90% Restricted. Assets $45m, Revenues $65m, $1.4m Cash, Former NYSE company traded @ $27+, Dockers, James Campbell, plus Private Lines ALL sold in J.C. Penny, Nordstrom, Sears, Kohls to name a few. Named New CEO, New CFO, New Directors from the BuxBaum Group. Many New Filings out, soon to be Up Listed back to NYSE once against Plus Numerous Insiders Buying in 2016, Approximately 90,000 shares @ $0.17 to $0.30, Form 4's rolling in weekly.

MAJOR Acquisitions Coming, Currently Targeting 100 companies

Great Investor Presentation/Projections >> http://www.hamp.com/pdf/HAMP-Investor-Presentation-2016.pdf

http://www.otcmarkets.com/stock/HAMP/filings

http://www.otcmarkets.com/stock/HAMP/news

Website >> http://www.hamp.com

2
JT's Scans -Morning Coffee & Chatter / Re: Get Rich, Follow Me...
« Last post by Extreme Stocks on June 05, 2016, 08:37:39 AM »
$HAMP $0.065 MOST UNDERVALUED STOCK on PLANET, Easily Valued @ $5.00 to $8.00 >> A/S 13.3m, O/S 8.7m, Float 700k with 90% Restricted. Assets $45m, Revenues $65m, $1.4m Cash, Former NYSE company traded @ $27+, Dockers, James Campbell, plus Private Lines ALL sold in J.C. Penny, Nordstrom, Sears, Kohls to name a few. Named New CEO, New CFO, New Directors from the BuxBaum Group. Many New Filings out, soon to be Up Listed back to NYSE once against Plus Numerous Insiders Buying in 2016, Approximately 90,000 shares @ $0.17 to $0.30, Form 4's rolling in weekly.

MAJOR Acquisitions Coming, Currently Targeting 100 companies

Great Investor Presentation/Projections >> http://www.hamp.com/pdf/HAMP-Investor-Presentation-2016.pdf

http://www.otcmarkets.com/stock/HAMP/filings

http://www.otcmarkets.com/stock/HAMP/news

Website >> http://www.hamp.com

3
EXTREME PICKS / Re: Winning Picks Guaranteed to Satisfy
« Last post by Extreme Stocks on February 05, 2016, 07:05:55 AM »
$NWPN .0068 Huge MJ Stock. 21m Float TA Confirmed, $5m in Financing to Generate $12m Revs 1st Year. June 2018 Expected $30m Revs with $95m Shareholders Equity which is Valued @ $0.28 PPS Based on Today's SS, Insiders Hold 308m Shares of 329m O/S

Website >>
http://www.thenowcorporation.net/

Awesome PowerPoint
http://www.thenowcorporation.net/now-corp-mj-hemp-business-plan.html

Revenues Growth $100,000,000 in Under 3 Years with Gross Margins of 50% & Net Income of 20%

Performance Milestones

Launch to 30 Days

1. Reverse Acquisition complete
2. Stop sign removed/current on filings
3. Creation of advisory board
4. Chairman of advisory board named
5. First Funding round complete


1st 60 Days
6. Ground breaking on first Hydroponic Facility7. Completion of first Hydroponic Facility 
8. First Hydroponic Facility harvest
9. First Hydroponic Facility extraction
10. New customer 1

61-120 Days
11. 2nd Round of Financing
12. Hydroponic Expansion
13. New Customer 2
14. New Board Member
15. Hydroponic Expansion 3-5

121 Day/Quarter
16. Financial Statements


4
JT's Scans -Morning Coffee & Chatter / Re: Get Rich, Follow Me...
« Last post by Extreme Stocks on January 23, 2016, 06:03:36 PM »
>>>>MUST READ COURTESY OF HOKIE<<<<

RXSF - Stock of 2016..

 

Current PPS: $2.67

HokieHead's Projected PPS: $75.00

 



 

 

About RXSF:

 RX Safes designs,develops, engineers, and markets fingerprint medical security storage solutionsfor consumers and healthcare professionals, using a common, patented,autonomous fingerprint interface which offers heightened security, tightercontrols and greater convenience. The company's products offer safety andsecurity of prescription medications and other controlled substances in thehome, within commercial healthcare facilities and out in the field.Prescription Drugs are more deadly than car accidents and guns combined andkill more than 100 people each day in the U.S. With a social and economic pricetag of over $600 billion, the company is dedicated to providing comprehensivesolutions to address the issues caused by drug diversion and unauthorizedaccess to these medications, with products ranging from fingerprint medicationsafes, portable medical storage solutions PCA pendants, needle-free injectors,locks and portable HIPAA compliant EHRs.

 

http://www.rxdrugsafe.com/

 

Share Structure (per OTC Markets) :

 Market: OTCQB

 Shares Outstanding:1,467,498

 Shares Floating:283,025

 Floating Shares ownedby Insiders: 175,000+

 Market Cap @ $2.67 =$3.9 million

 ----------------------------------------------------------------

 

 

 

 

----------------------------------------------------------------

Recent Executive Summary and InvestorPresentation:

 

http://www.rxdrugsafe.com/files/Rx%20Safes%20Presentation%20December%202015_Website%20Version.compressed.pdf

 

http://www.rxdrugsafe.com/files/Executive%20Summary_RX%20Safes_December%202015.compressed.pdf

 

Slide 24/27 - $25 million investment results in 3years:

 -$95 million revenues

 -$27 million cash onhand

 -$43 million EBITDA

 

 ----------------------------------------------------------------

Medical Device Research Analyst 12/21/15: Target:$17 

 

http://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf

 

 ----------------------------------------------------------------

Company introduces 2016 Growth Plans:

 

http://www.rxdrugsafe.com/rx-safes-releases-shareholder-letter-2/

 

 ----------------------------------------------------------------

In 2016 I am expecting the following here: 

 

 1. BankFinancing - Non toxic bank loan, possibly in installments, starting inthe $2.5 million range, up to a possible $25 million in 2016.

 2. FutureConvertible Debt - With bank financing, CD's coming due in a few monthswill be paid off, leaving zero potential of additional shares.

 3. StockExchange Uplist- Within 1-2 months the company will meet all therequirements to uplist to the NYSE/NASDAQ exchange.

 4. CreateCompany Synergies - Partner with manufacturers, like Mika Medical, thatwill keep costs down and improve gross margins.

 5. ExpandRxSafe Programs - With the success of the Online CVS program, expandthe sales to CVS stores and even more pharmacies and brick/mortar departmentstores. Possible safe sales of over 150,000 safes in 2016, or $15 million insales.

 6. ProfessionalHealthcare Products - Per PR 11/12/15, partner with infusion pumpmanufacturers to include RX SafeDose and RX MyDose. BIG BUCKS.

 7. Sales ofother (new) products - Added sales from RXSFs other ProfessionalHealthcare products and any other new items under development the pubic isn'taware of.

 8. Possiblebuyout candidate - The patents, technology and products RXSF offerswould be a tempting company to be acquired by a large Medical Device or PharmaCompany with tons of cash. Dropping $100 million + for this company within ayear is not out of the question.

 

 ----------------------------------------------------------------

So what could RXSF look like as far as numbers within 1-2years:

 

Revenues: $75.0 million

 Expenses: $60.0million

 Income: $15.0 million

 Outstanding Shares:10.0 million (increased outstanding figure to include financing shares)

 

 P/S Ratio (IndustryAverage 3): $75.0 million x 10 = $750 million / 10.0 million = $75 price pershare

 

 P/E Ratio (IndustryAverage 32): $15.0 million / 10 million = $1.50 x 50 = $75 price pershare

 

 $1,000 investment01/2016 = $27,000 possible value within a year

 

 Comments: I used theP/S Ratio of 10 and a PE Ratio of 50, higher than the industry averages due tothe higher than expected growth rate for RXSF. I also used a conservativeincome figure. See you on NYSE or Nasdaq over $50 a share unless we get boughtout first.
5
EXTREME PICKS / Re: Winning Picks Guaranteed to Satisfy
« Last post by Extreme Stocks on January 23, 2016, 06:03:06 PM »
>>>>MUST READ COURTESY OF HOKIE<<<<

RXSF - Stock of 2016..

 

Current PPS: $2.67

HokieHead's Projected PPS: $75.00

 



 

 

About RXSF:

 RX Safes designs,develops, engineers, and markets fingerprint medical security storage solutionsfor consumers and healthcare professionals, using a common, patented,autonomous fingerprint interface which offers heightened security, tightercontrols and greater convenience. The company's products offer safety andsecurity of prescription medications and other controlled substances in thehome, within commercial healthcare facilities and out in the field.Prescription Drugs are more deadly than car accidents and guns combined andkill more than 100 people each day in the U.S. With a social and economic pricetag of over $600 billion, the company is dedicated to providing comprehensivesolutions to address the issues caused by drug diversion and unauthorizedaccess to these medications, with products ranging from fingerprint medicationsafes, portable medical storage solutions PCA pendants, needle-free injectors,locks and portable HIPAA compliant EHRs.

 

http://www.rxdrugsafe.com/

 

Share Structure (per OTC Markets) :

 Market: OTCQB

 Shares Outstanding:1,467,498

 Shares Floating:283,025

 Floating Shares ownedby Insiders: 175,000+

 Market Cap @ $2.67 =$3.9 million

 ----------------------------------------------------------------

 

 

 

 

----------------------------------------------------------------

Recent Executive Summary and InvestorPresentation:

 

http://www.rxdrugsafe.com/files/Rx%20Safes%20Presentation%20December%202015_Website%20Version.compressed.pdf

 

http://www.rxdrugsafe.com/files/Executive%20Summary_RX%20Safes_December%202015.compressed.pdf

 

Slide 24/27 - $25 million investment results in 3years:

 -$95 million revenues

 -$27 million cash onhand

 -$43 million EBITDA

 

 ----------------------------------------------------------------

Medical Device Research Analyst 12/21/15: Target:$17 

 

http://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf

 

 ----------------------------------------------------------------

Company introduces 2016 Growth Plans:

 

http://www.rxdrugsafe.com/rx-safes-releases-shareholder-letter-2/

 

 ----------------------------------------------------------------

In 2016 I am expecting the following here: 

 

 1. BankFinancing - Non toxic bank loan, possibly in installments, starting inthe $2.5 million range, up to a possible $25 million in 2016.

 2. FutureConvertible Debt - With bank financing, CD's coming due in a few monthswill be paid off, leaving zero potential of additional shares.

 3. StockExchange Uplist- Within 1-2 months the company will meet all therequirements to uplist to the NYSE/NASDAQ exchange.

 4. CreateCompany Synergies - Partner with manufacturers, like Mika Medical, thatwill keep costs down and improve gross margins.

 5. ExpandRxSafe Programs - With the success of the Online CVS program, expandthe sales to CVS stores and even more pharmacies and brick/mortar departmentstores. Possible safe sales of over 150,000 safes in 2016, or $15 million insales.

 6. ProfessionalHealthcare Products - Per PR 11/12/15, partner with infusion pumpmanufacturers to include RX SafeDose and RX MyDose. BIG BUCKS.

 7. Sales ofother (new) products - Added sales from RXSFs other ProfessionalHealthcare products and any other new items under development the pubic isn'taware of.

 8. Possiblebuyout candidate - The patents, technology and products RXSF offerswould be a tempting company to be acquired by a large Medical Device or PharmaCompany with tons of cash. Dropping $100 million + for this company within ayear is not out of the question.

 

 ----------------------------------------------------------------

So what could RXSF look like as far as numbers within 1-2years:

 

Revenues: $75.0 million

 Expenses: $60.0million

 Income: $15.0 million

 Outstanding Shares:10.0 million (increased outstanding figure to include financing shares)

 

 P/S Ratio (IndustryAverage 3): $75.0 million x 10 = $750 million / 10.0 million = $75 price pershare

 

 P/E Ratio (IndustryAverage 32): $15.0 million / 10 million = $1.50 x 50 = $75 price pershare

 

 $1,000 investment01/2016 = $27,000 possible value within a year

 

 Comments: I used theP/S Ratio of 10 and a PE Ratio of 50, higher than the industry averages due tothe higher than expected growth rate for RXSF. I also used a conservativeincome figure. See you on NYSE or Nasdaq over $50 a share unless we get boughtout first.
6
EXTREME PICKS / Re: Winning Picks Guaranteed to Satisfy
« Last post by Extreme Stocks on January 13, 2016, 10:24:55 AM »
RXSF $3.49 Going Fast +33% $0.87

You must Read this >> Here's the future of Fingerprint Technology and Medical Devices

Major Catalysts Coming >> 

$25,000,000 Investment Bank Financing (3 Phase ) 

CVS In store Deal Upwards $10m for All 7,800 Stores 

National Commercial Release for RX DrugSafe 

IP Acquisitions/Company Acquisitions/Mergers 

OEMS Partnerships Valued $3m+ Per Month (SafeDose), Thousands Available! 

New Board Members 

Ultimately Up Listing To NASDAQ with Fiscal 2016 Projection of $17.41 Very Conservative 

**280,000 Float, No Dilution**
7
JT's Scans -Morning Coffee & Chatter / Re: Get Rich, Follow Me...
« Last post by Extreme Stocks on January 13, 2016, 10:24:10 AM »
RXSF $3.49 Going Fast +33% $0.87

You must Read this >> Here's the future of Fingerprint Technology and Medical Devices

Major Catalysts Coming >> 

$25,000,000 Investment Bank Financing (3 Phase ) 

CVS In store Deal Upwards $10m for All 7,800 Stores 

National Commercial Release for RX DrugSafe 

IP Acquisitions/Company Acquisitions/Mergers 

OEMS Partnerships Valued $3m+ Per Month (SafeDose), Thousands Available! 

New Board Members 

Ultimately Up Listing To NASDAQ with Fiscal 2016 Projection of $17.41 Very Conservative 

**280,000 Float, No Dilution**
8
JT's Scans -Morning Coffee & Chatter / Re: Get Rich, Follow Me...
« Last post by Extreme Stocks on January 12, 2016, 12:04:12 PM »
ITNS .003 Falling  Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its EmesylŪ over-the-counter homeopathic product for nausea relief.

In addition, the Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office for its EmesylŪ trademark.

The NDC number and trademark Notice of Allowance has enabled the Company to enter the final stage of its product packaging design, and the production of EmesylŪ will soon begin with its manufacturer, Oasis Health Products.

The Company will market EmesylŪ to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors 
9
EXTREME PICKS / Re: Winning Picks Guaranteed to Satisfy
« Last post by Extreme Stocks on January 12, 2016, 12:03:51 PM »
ITNS .003 Falling  Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its EmesylŪ over-the-counter homeopathic product for nausea relief.

In addition, the Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office for its EmesylŪ trademark.

The NDC number and trademark Notice of Allowance has enabled the Company to enter the final stage of its product packaging design, and the production of EmesylŪ will soon begin with its manufacturer, Oasis Health Products.

The Company will market EmesylŪ to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors 
10
EXTREME PICKS / Re: Winning Picks Guaranteed to Satisfy
« Last post by Extreme Stocks on January 05, 2016, 09:18:19 PM »
RXSF Big Big News of Major Market Maker Screw Up https://t.co/vOH0tv2y0e

Imagine 250k float and selling approx. 30,000 unauthorized shares
Pages: [1] 2 3 ... 10